

## Contents

<b>Contributors</b>	<i>XV</i>
<b>Preface</b>	<i>XXI</i>
<b>A Personal Foreword</b>	<i>XXIII</i>

### **Part I The Concept of Fragment-based Drug Discovery 1**

<b>1</b>	<b>The Role of Fragment-based Discovery in Lead Finding 3</b>
	<i>Roderick E. Hubbard</i>
1.1	Introduction 3
1.2	What is FBLD? 4
1.3	FBLD: Current Practice 5
1.3.1	Using Fragments: Conventional Targets 5
1.3.2	Using Fragments: Unconventional Targets 13
1.4	What do Fragments Bring to Lead Discovery? 14
1.5	How did We Get Here? 16
1.5.1	Evolution of the Early Ideas and History 16
1.5.2	What has Changed Since the First Book was Published in 2006? 16
1.6	Evolution of the Methods and Their Application Since 2005 19
1.6.1	Developments in Fragment Libraries 21
1.6.2	Fragment Hit Rate and Druggability 22
1.6.3	Developments in Fragment Screening 23
1.6.4	Ways of Evolving Fragments 23
1.6.5	Integrating Fragments Alongside Other Lead-Finding Strategies 23
1.6.6	Fragments Can be Selective 24
1.6.7	Fragment Binding Modes 25
1.6.8	Fragments, Chemical Space, and Novelty 27
1.7	Current Application and Impact 27
1.8	Future Opportunities 28
	References 29

<b>2</b>	<b>Selecting the Right Targets for Fragment-Based Drug Discovery</b>	<b>37</b>
	<i>Thomas G. Davies, Harren Jhoti, Puja Pathuri, and Glyn Williams</i>	
2.1	Introduction	37
2.2	Properties of Targets and Binding Sites	39
2.3	Assessing Druggability	41
2.4	Properties of Ligands and Drugs	42
2.5	Case Studies	43
2.5.1	Case Study 1: Inhibitors of Apoptosis Proteins (IAPs)	44
2.5.2	Case Study 2: HCV-NS3	46
2.5.3	Case Study 3: PKM2	47
2.5.4	Case Study 4: Soluble Adenylate Cyclase	49
2.6	Conclusions	50
	References	51
<b>3</b>	<b>Enumeration of Chemical Fragment Space</b>	<b>57</b>
	<i>Jean-Louis Reymond, Ricardo Visini, and Mahendra Awale</i>	
3.1	Introduction	57
3.2	The Enumeration of Chemical Space	58
3.2.1	Counting and Sampling Approaches	58
3.2.2	Enumeration of the Chemical Universe Database GDB	58
3.2.3	GDB Contents	59
3.3	Using and Understanding GDB	61
3.3.1	Drug Discovery	61
3.3.2	The MQN System	62
3.3.3	Other Fingerprints	63
3.4	Fragments from GDB	65
3.4.1	Fragment Replacement	65
3.4.2	Shape Diversity of GDB Fragments	66
3.4.3	Aromatic Fragments from GDB	68
3.5	Conclusions and Outlook	68
	Acknowledgment	69
	References	69
<b>4</b>	<b>Ligand Efficiency Metrics and their Use in Fragment Optimizations</b>	<b>75</b>
	<i>György G. Ferenczy and György M. Keserű</i>	
4.1	Introduction	75
4.2	Ligand Efficiency	75
4.3	Binding Thermodynamics and Efficiency Indices	78
4.4	Enthalpic Efficiency Indices	81
4.5	Lipophilic Efficiency Indices	83
4.6	Application of Efficiency Indices in Fragment-Based Drug Discovery Programs	88
4.7	Conclusions	94
	References	95

**Part II Methods and Approaches for Fragment-based Drug Discovery 99**

- 5 Strategies for Fragment Library Design 101**  
*Justin Bower, Angelo Pugliese, and Martin Drysdale*
- 5.1 Introduction 101
  - 5.2 Aims 102
  - 5.3 Progress 102
    - 5.3.1 BDDP Fragment Library Design: Maximizing Diversity 103
    - 5.3.2 Assessing Three-Dimensionality 103
    - 5.3.3 3DFrag Consortium 104
    - 5.3.4 Commercial Fragment Space Analysis 105
    - 5.3.5 BDDP Fragment Library Design 108
    - 5.3.6 Fragment Complexity 111
      - 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules 113
  - 5.4 Future Plans 114
  - 5.5 Summary 116
  - 5.6 Key Achievements 116
    - References 116
- 6 The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery 119**  
*Ben J. Davis and Anthony M. Giannetti*
- 6.1 Introduction 119
  - 6.2 Fragment-Based Lead Discovery on a Difficult Kinase 121
  - 6.3 Application of Orthogonal Biophysical Methods to Identify and Overcome an Unusual Ligand: Protein Interaction 127
  - 6.4 Direct Comparison of Orthogonal Screening Methods Against a Well-Characterized Protein System 131
  - 6.5 Conclusions 135
    - References 136
- 7 Differential Scanning Fluorimetry as Part of a Biophysical Screening Cascade 139**  
*Duncan E. Scott, Christina Spry, and Chris Abell*
- 7.1 Introduction 139
  - 7.2 Theory 140
    - 7.2.1 Equilibria are Temperature Dependent 140
    - 7.2.2 Thermodynamics of Protein Unfolding 142
    - 7.2.3 Exact Mathematical Solutions to Ligand-Induced Thermal Shifts 143
    - 7.2.4 Ligand Binding and Protein Unfolding Thermodynamics Contribute to the Magnitude of Thermal Shifts 145
    - 7.2.5 Ligand Concentration and the Magnitude of Thermal Shifts 147
    - 7.2.6 Models of Protein Unfolding Equilibria and Ligand Binding 148

- 7.2.7 Negative Thermal Shifts and General Confusions 150
- 7.2.8 Lessons Learnt from Theoretical Analysis of DSF 151
- 7.3 Practical Considerations for Applying DSF in Fragment-Based Approaches 152
- 7.4 Application of DSF to Fragment-Based Drug Discovery 154
  - 7.4.1 DSF as a Primary Enrichment Technique 154
  - 7.4.2 DSF Compared with Other Hit Identification Techniques 159
  - 7.4.3 Pursuing Destabilizing Fragment Hits 166
  - 7.4.4 Lessons Learnt from Literature Examples of DSF in Fragment-Based Drug Discovery 168
- 7.5 Concluding Remarks 169
  - Acknowledgments 169
  - References 170

## 8 Emerging Technologies for Fragment Screening 173

*Sten Ohlson and Minh-Dao Duong-Thi*

- 8.1 Introduction 173
- 8.2 Emerging Technologies 175
  - 8.2.1 Weak Affinity Chromatography 175
    - 8.2.1.1 Introduction 175
    - 8.2.1.2 Theory 177
    - 8.2.1.3 Fragment Screening 179
  - 8.2.2 Mass Spectrometry 185
    - 8.2.2.1 Introduction 185
    - 8.2.2.2 Theory 186
    - 8.2.2.3 Applications 186
  - 8.2.3 Microscale Thermophoresis 187
    - 8.2.3.1 Introduction 187
    - 8.2.3.2 Theory 189
    - 8.2.3.3 Applications 189
- 8.3 Conclusions 189
  - Acknowledgments 191
  - References 191

## 9 Computational Methods to Support Fragment-based Drug Discovery 197

*Laurie E. Grove, Sandor Vajda, and Dima Kozakov*

- 9.1 Computational Aspects of FBDD 197
- 9.2 Detection of Ligand Binding Sites and Binding Hot Spots 198
  - 9.2.1 Geometry-based Methods 199
  - 9.2.2 Energy-based Methods 201
  - 9.2.3 Evolutionary and Structure-based Methods 202
  - 9.2.4 Combination Methods 202
- 9.3 Assessment of Druggability 203
- 9.4 Generation of Fragment Libraries 205

- 9.4.1 Known Drugs 206
- 9.4.2 Natural Compounds 207
- 9.4.3 Novel Scaffolds 208
- 9.5 Docking Fragments and Scoring 209
  - 9.5.1 Challenges of Fragment Docking 209
  - 9.5.2 Examples of Fragment Docking 210
- 9.6 Expansion of Fragments 212
- 9.7 Outlook 214
- References 214
  
- 10 Making FBDD Work in Academia 223**  
*Stacie L. Bulfer, Frantz Jean-Francois, and Michelle R. Arkin*
- 10.1 Introduction 223
- 10.2 How Academic and Industry Drug Discovery Efforts Differ 225
- 10.3 The Making of a Good Academic FBDD Project 226
- 10.4 FBDD Techniques Currently Used in Academia 228
  - 10.4.1 Nuclear Magnetic Resonance 229
  - 10.4.2 X-Ray Crystallography 230
  - 10.4.3 Surface Plasmon Resonance/Biolayer Interferometry 231
  - 10.4.4 Differential Scanning Fluorimetry 232
  - 10.4.5 Isothermal Titration Calorimetry 232
  - 10.4.6 Virtual Screening 232
  - 10.4.7 Mass Spectrometry 233
    - 10.4.7.1 Native MS 233
    - 10.4.7.2 Site-Directed Disulfide Trapping (Tethering) 234
  - 10.4.8 High-Concentration Bioassays 234
- 10.5 Project Structures for Doing FBDD in Academia 235
  - 10.5.1 Targeting p97: A Chemical Biology Consortium Project 235
  - 10.5.2 Targeting Caspase-6: An Academic–Industry Partnership 236
- 10.6 Conclusions and Perspectives 239
- References 240
  
- 11 Site-Directed Fragment Discovery for Allostery 247**  
*T. Justin Rettenmaier, Sean A. Hudson, and James A. Wells*
- 11.1 Introduction 247
- 11.2 Caspases 249
  - 11.2.1 Tethered Allosteric Inhibitors of Executioner Caspases-3 and -7 249
  - 11.2.2 Tethering Inflammatory Caspase-1 250
  - 11.2.3 Tethered Allosteric Inhibitors of Caspase-5 251
  - 11.2.4 General Allosteric Regulation at the Caspase Dimer Interface 252
  - 11.2.5 Using Disulfide Fragments as “Chemi-Locks” to Generate Conformation-Specific Antibodies 253
- 11.3 Tethering K-Ras(G12C) 254
- 11.4 The Master Transcriptional Coactivator CREB Binding Protein 256

11.4.1	Tethering to Find Stabilizers of the KIX Domain of CBP	256
11.4.2	Dissecting the Allosteric Coupling between Binding Sites on KIX	257
11.4.3	Rapid Identification of pKID-Competitive Fragments for KIX	258
11.5	Tethering Against the PIF Pocket of Phosphoinositide-Dependent Kinase 1 (PDK1)	259
11.6	Tethering Against GPCRs: Complement 5A Receptor	261
11.7	Conclusions and Future Directions	263
	References	264
<b>12</b>	<b>Fragment Screening in Complex Systems</b>	<b>267</b>
	<i>Miles Congreve and John A. Christopher</i>	
12.1	Introduction	267
12.2	Fragment Screening and Detection of Fragment Hits	268
12.2.1	Fragment Screening Using NMR Techniques	270
12.2.2	Fragment Screening Using Surface Plasmon Resonance	271
12.2.3	Fragment Screening Using Capillary Electrophoresis	272
12.2.4	Fragment Screening Using Radioligand and Fluorescence-Based Binding Assays	273
12.2.5	Ion Channel Fragment Screening	275
12.3	Validating Fragment Hits	276
12.4	Fragment to Hit	279
12.4.1	Fragment Evolution	280
12.4.2	Fragment Linking	281
12.5	Fragment to Lead Approaches	281
12.5.1	Fragment Evolution	282
12.5.2	Fragment Linking	284
12.6	Perspective and Conclusions	285
	Acknowledgments	287
	References	287
<b>13</b>	<b>Protein-Templated Fragment Ligation Methods: Emerging Technologies in Fragment-Based Drug Discovery</b>	<b>293</b>
	<i>Mike Jaegle, Eric Nawrotzky, Ee Lin Wong, Christoph Arkona, and Jörg Rademann</i>	
13.1	Introduction: Challenges and Visions in Fragment-Based Drug Discovery	293
13.2	Target-Guided Fragment Ligation: Concepts and Definitions	294
13.3	Reversible Fragment Ligation	295
13.3.1	Dynamic Reversible Fragment Ligation Strategies	295
13.3.2	Chemical Reactions Used in Dynamic Fragment Ligations	296
13.3.3	Detection Strategies in Dynamic Fragment Ligations	299
13.3.4	Applications of Dynamic Fragment Ligations in FBDD	301
13.4	Irreversible Fragment Ligation	311
13.4.1	Irreversible Fragment Ligation Strategies: Pros and Cons	311

- 13.4.2 Detection in Irreversible Fragment Ligation 311
- 13.4.3 Applications of Irreversible Fragment Ligations in FBDD 313
- 13.5 Fragment Ligations Involving Covalent Reactions with Proteins 316
- 13.6 Conclusions and Future Outlook: How Far did We Get and What will be Possible? 319
- References 320

### Part III Successes from Fragment-based Drug Discovery 327

#### 14 BACE Inhibitors 329

*Daniel F. Wyss, Jared N. Cumming, Corey O. Strickland, and Andrew W. Stamford*

- 14.1 Introduction 329
- 14.2 FBDD Efforts on BACE1 333
  - 14.2.1 Fragment Hit Identification, Validation, and Expansion 333
  - 14.2.2 Fragment Optimization 333
  - 14.2.3 From a Key Pharmacophore to Clinical Candidates 340
- 14.3 Conclusions 346
- References 346

#### 15 Epigenetics and Fragment-Based Drug Discovery 355

*Aman Iqbal and Peter J. Brown*

- 15.1 Introduction 355
- 15.2 Epigenetic Families and Drug Targets 357
- 15.3 Epigenetics Drug Discovery Approaches and Challenges 358
- 15.4 FBDD Case Studies 359
  - 15.4.1 BRD4 (Bromodomain) 360
  - 15.4.2 EP300 (Bromodomain) 363
  - 15.4.3 ATAD2 (Bromodomain) 364
  - 15.4.4 BAZ2B (Bromodomain) 364
  - 15.4.5 SIRT2 (Histone Deacetylase) 365
  - 15.4.6 Next-Generation Epigenetic Targets: The “Royal Family” and Histone Demethylases 366
- 15.5 Conclusions 367
- Abbreviations 368
- References 368

#### 16 Discovery of Inhibitors of Protein–Protein Interactions Using Fragment-Based Methods 371

*Feng Wang and Stephen W. Fesik*

- 16.1 Introduction 371
- 16.2 Fragment-Based Strategies for Targeting PPIs 372
  - 16.2.1 Fragment Library Construction 372
  - 16.2.2 NMR-Based Fragment Screening Methods 373

- 16.2.3 Structure Determination of Complexes 374
- 16.2.4 Structure-Guided Hit-to-Lead Optimization 375
- 16.3 Recent Examples from Our Laboratory 376
  - 16.3.1 Discovery of RPA Inhibitors 377
  - 16.3.2 Discovery of Potent Mcl-1 Inhibitors 378
  - 16.3.3 Discovery of Small Molecules that Bind to K-Ras 379
- 16.4 Summary and Conclusions 382
  - Acknowledgments 383
  - References 384
  
- 17 Fragment-Based Discovery of Inhibitors of Lactate Dehydrogenase A 391**
  - Alexander L. Breeze, Richard A. Ward, and Jon Winter*
  - 17.1 Aerobic Glycolysis, Lactate Metabolism, and Cancer 391
  - 17.2 Lactate Dehydrogenase as a Cancer Target 392
  - 17.3 “Ligandability” Characteristics of the Cofactor and Substrate Binding Sites in LDHA 394
  - 17.4 Previously Reported LDH Inhibitors 395
  - 17.5 Fragment-Based Approach to LDHA Inhibition at AstraZeneca 398
    - 17.5.1 High-Throughput Screening Against LDHA 398
    - 17.5.2 Rationale and Strategy for Exploration of Fragment-Based Approaches 399
    - 17.5.3 Development of Our Biophysical and Structural Biology Platform 400
    - 17.5.4 Elaboration of Adenine Pocket Fragments 404
    - 17.5.5 Screening for Fragments Binding in the Substrate and Nicotinamide Pockets 405
    - 17.5.6 Reaching out Across the Void 407
    - 17.5.7 Fragment Linking and Optimization 408
  - 17.6 Fragment-Based LDHA Inhibitors from Other Groups 410
    - 17.6.1 Nottingham 410
    - 17.6.2 Ariad 413
  - 17.7 Conclusions and Future Perspectives 417
    - References 419
  
- 18 FBDD Applications to Kinase Drug Hunting 425**
  - Gordon Saxty*
  - 18.1 Introduction 425
  - 18.2 Virtual Screening and X-ray for PI3K 426
  - 18.3 High-Concentration Screening and X-ray for Rock1/2 427
  - 18.4 Surface Plasmon Resonance for MAP4K4 428
  - 18.5 Weak Affinity Chromatography for GAK 429
  - 18.6 X-ray for CDK 4/6 430
  - 18.7 High-Concentration Screening, Thermal Shift, and X-ray for CHK2 432
  - 18.8 Virtual Screening and Computational Modeling for AMPK 433
  - 18.9 High-Concentration Screening, NMR, and X-ray FBDD for PDK1 434



18.10	Tethering Mass Spectrometry and X-ray for PDK1	435
18.11	NMR and X-ray Case Study for Abl (Allosteric)	436
18.12	Review of Current Kinase IND's and Conclusions	437
	References	442
<b>19</b>	<b>An Integrated Approach for Fragment-Based Lead Discovery: Virtual, NMR, and High-Throughput Screening Combined with Structure-Guided Design. Application to the Aspartyl Protease Renin.</b>	<b>447</b>
	<i>Simon Rüdiger, Eric Vangrevelinghe, and Jürgen Maibaum</i>	
19.1	Introduction	447
19.2	Renin as a Drug Target	449
19.3	The Catalytic Mechanism of Renin	451
19.4	Virtual Screening	452
19.5	Fragment-Based Lead Finding Applied to Renin and Other Aspartyl Proteases	455
19.6	Renin Fragment Library Design	464
19.7	Fragment Screening by NMR T <sub>1</sub> ρ Ligand Observation	469
19.8	X-Ray Crystallography	473
19.9	Renin Fragment Hit-to-Lead Evolution	475
19.10	Integration of Fragment Hits and HTS Hits	476
19.11	Conclusions	479
	References	480
	<b>Index</b>	<b>487</b>

